Nitrile Powder Free Examination Gloves with Low Dermatitis Potential, Tested for Use with Chemotherapy Drugs, Fentanyl Citrate and Gastric Acid

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner’s hand to

prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs, fentanyl citrate and gastric acid as per ASTM D6978-05

(2023) Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs:

The following drugs and concentration had NO breakthrough detected up to 240 minutes:

Bendamustine HCI (5 mg/mL)

Bleomycin Sulfate (15 mg/mL)

Busulfan (6 mg/mL)

Carboplatin (10 mg/mL)

Carfilzomib (2 mg/mL)

Cetuximab (Erbitux) (2 mg/mL)

Chloroquine (50 mg/mL)

Cisplatin (1 mg/mL)

Cladribine (1 mg/mL)

Cyclophosphamide (20 mg/mL)

Cyclosporin A (100 mg/mL)

Cytarabine HCI (100 mg/mL.)

Cytovene (10 mg/mL)

Dacarbazine (10 mg/mL)

Daunorubicin HCI (5 mg/mL)

Decitabine (5 mg/mL)

Docetaxel (10 mg/mL)

Doxorubicin HCI (2 mg/mL)

Epirubicin HCI (2 mg/mL)

Etoposide (20 mg/mL)

Fludarabine Phosphate (25 mg/mL)

Fluorouracil (50 mg/mL)

Fulvestrant (50 mg/mL)

Gemcitabine HCI (38 mg/mL)

Idarubicin HCI (1 mg/mL)

Ifosfamide (50 mg/mL)

Irinotecan HCI (20 mg/mL)

Mechlorethamine HCI (1 mg/mL)

Melphalan HCI (5 mg/mL)

MESNA (100 mg/mL)

Methotrexate (25 mg/mL)

Mitomycin C (0.5 mg/mL)

Mitoxantrone HCI (2 mg/mL)

Oxaliplatin (2 mg/mL)

Paclitaxel (6 mg/mL)

Pemetrexed (25 mg/mL)

Propofol (10 mg/mL)

Raltitrexed (0.5 mg/mL)

Retrovir (10 mg/mL)

Rituximab (10 mg/mL)

Temsirolimus (25 mg/mL)

Topotecan HCI (1 mg/mL)

Triclosan (1 mg/mL)

Trisenox (Arsenic Trioxide) (1 mg/mL)

Velcade (Bortezomib) (1 mg/mL)

Vidaza (Azacitidine) (25 mg/mL)

Vinblastine Sulfate (1 mg/mL)

Vincristine Sulfate (1 mg/mL)

Vinorelbine Tartrate (10 mg/mL)

Zoledronic Acid (0.8 mg/mL)

The following chemotherapy drugs and concentration showed breakthrough detected in less than 60 minutes:

Carmustine (3.3 mg/mL), breakthrough detected at 55.5 minutes

Thiotepa (10 mg/mL), breakthrough detected at 50.8 minutes

Warning: Not recommended for use with Carmustine and Thiotepa

The following hazardous drugs (opioids) and concentration had NO breakthrough detected up to 240 minutes:

Fentanyl Citrate Injection (100mcg/2mL)

Simulated Gastric Acid Fluid/Fentanyl Citrate Injection Mix 50/50 Solution